![\"AI](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/09\/ai-drug-repurposing-market-size.webp.webp\" "\\"AI")
<\/p>\nAI In Drug Repurposing Market Summary<\/p>\n
The global AI in drug repurposing market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 5.48 billion by 2033, growing at a CAGR of 20.39% from 2025 to 2033. Rising demand for cost-effective drug development, advancements in AI algorithms, and the growing prevalence of rare and complex diseases are significant factors contributing to market growth.<\/p>\n
Key Market Trends & Insights
\n
\nNorth America AI in drug repurposing market accounted for the largest revenue share of 40.47% in 2024.
\nThe U.S. AI in drug repurposing industry held the largest share in 2024.
\nBy component, the software & platform segment held the largest revenue share of 66.86% in 2024.
\nBy Technology, The machine learning\/deep leaning segment accounted for the largest revenue share of 46.01% in 2024.
\nBy end use, the pharmaceutical & biotechnology companies segment led the AI in drug repurposing market with the largest share of 59.80% in 2024.
<\/p>\n
Market Size & Forecast
\n
\n2024 Market Size: USD 1.02 Billion
\n2033 Projected Market Size: USD 5.48 Billion
\nCAGR (2025-2033): 20.39%
\nNorth America: Largest market in 2024
<\/p>\n
In addition, increasing collaborations between pharmaceutical companies, academic institutions, and AI technology providers, and improvements in computing power and cloud infrastructure are some other factors fueling the growth.<\/p>\n
The rising demand for cost-effective drug development strategies substantially drives the growth of the AI in drug repurposing industry. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments.<\/p>\n
<\/p>\n
AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.<\/p>\n
Furthermore, the rising prevalence of rare diseases propels market growth further. For instance, according to the data published by The Lancet Journal in March\u00a02024, around 300 million people live with rare diseases, affecting around 3.5% – 5.9% of the global population. Moreover, around 80% of\u00a0rare diseases\u00a0are genetically caused, almost 70% of which are present in childhood. \u00a0AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs, thus expediting treatment access.<\/p>\n
List of few AI-based drug repurposing instances
\n
\n
\n
\n
<\/p>\n
Company<\/p>\n
\n
\n
<\/p>\n
Discovery
Year<\/p>\n
\n
\n
<\/p>\n
Clinical
Validation Year<\/p>\n
\n
\n
<\/p>\n
Regulatory \/ Approval Year<\/p>\n
\n
\n
<\/p>\n
Initiative<\/p>\n
\n
\n
\n
\n
<\/p>\n
BenevolentAI\u00a0<\/p>\n
\n
\n
<\/p>\n
2020<\/p>\n
\n
\n
<\/p>\n
2020-2021<\/p>\n
\n
\n
<\/p>\n
2020-2022<\/p>\n
\n
\n
<\/p>\n
Identified Baricitinib for COVID-19 treatment; EUA by FDA Nov 2020; full approval May 2022.<\/p>\n
\n
\n
\n
\n
<\/p>\n
Insilico Medicine<\/p>\n
\n
\n
<\/p>\n
2023<\/p>\n
\n
\n
<\/p>\n
2023<\/p>\n
\n
\n
<\/p>\n
N\/A<\/p>\n
\n
\n
<\/p>\n
Used generative AI (PandaOmics) to repurpose Lifitegrast for endometriosis, validated preclinically.<\/p>\n
\n
\n
\n
\n
<\/p>\n
Atomwise & DNDi<\/p>\n
\n
\n
<\/p>\n
2023-2025<\/p>\n
\n
\n
<\/p>\n
Ongoing<\/p>\n
\n
\n
<\/p>\n
N\/A<\/p>\n
\n
\n
<\/p>\n
AI-driven molecule screening to find drug candidates for Chagas disease.<\/p>\n
\n
\n
\n
\n
<\/p>\n
DeepDrug<\/p>\n
\n
\n
<\/p>\n
2025<\/p>\n
\n
\n
<\/p>\n
Ongoing<\/p>\n
\n
\n
<\/p>\n
N\/A<\/p>\n
\n
\n
<\/p>\n
AI framework identifying repurposed drug combinations for Alzheimer’s disease.<\/p>\n
\n
\n
\n
\n
<\/p>\n
Every\u00a0Cure Initiative<\/p>\n
\n
\n
<\/p>\n
2023<\/p>\n
\n
\n
<\/p>\n
Ongoing<\/p>\n
\n
\n
<\/p>\n
N\/A<\/p>\n
\n
\n
<\/p>\n
AI-powered platforms are mining drug repurposing opportunities for rare diseases.<\/p>\n
\n
\n
\n
<\/p>\n
Market Concentration & Characteristics<\/p>\n
The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The x-axis represents the level of industry concentration, ranging from low to high. The y-axis represents various industry characteristics, including industry competition, level of partnerships & collaboration activities, degree of innovation, impact of regulations, and regional expansion. The AI in drug repurposing market is consolidated. However, several emerging players are entering the market, thereby contributing to increased fragmentation within the market. The degree of innovation and the level of partnership and collaboration activities, and the impact of regulations is high. Moreover, the regional expansion of industry is moderate.<\/p>\n
The degree of innovation in the AI in drug repurposing industry is notably high, driven by the integration of advanced computational methods with vast biomedical datasets. Generative AI models hypothesize novel drug-target interactions, while natural language processing (NLP) systems mine biomedical literature, patents, and clinical trial data for hidden insights. Additionally, collaborations between AI firms, pharmaceutical companies, and academic institutions foster the creation of dedicated platforms tailored to repurpose workflows.<\/p>\n
![\"AI](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/09\/ai-drug-repurposing-industry-dynamics.webp.webp\" "\\"AI")
<\/p>\n
The industry is experiencing a moderate level of merger and acquisition activities undertaken by several key players. This is due to the desire to gain a competitive advantage in the industry, enhance technological capabilities, and consolidate in a rapidly growing market.\u00a0For instance, in July 2025, Healx partnered with SCI Ventures in a USD 2 million collaboration to accelerate therapies for spinal cord injury (SCI) using AI-driven drug discovery focused on target discovery and drug repurposing.<\/p>\n
Global regulations governing AI in the drug repurposing market emphasize ensuring the safety, efficacy, and transparency of AI-assisted therapeutic development. Regulatory agencies such as the U.S. FDA have issued draft guidances focused on incorporating AI into drug development and regulatory decision-making processes with a risk-based approach. The framework encourages rigorous validation, interpretability, and ongoing monitoring of AI models to prevent bias and errors.\u00a0<\/p>\n
The industry is witnessing moderate geographical expansion. Companies within the AI in drug repurposing industry seek geographic expansion strategies to maintain their foothold in emerging markets and attract customers from these regions.<\/p>\n
Component Insights<\/p>\n
The software & platform segment held the largest revenue share of 66.86%\u00a0in 2024. These solutions leverage large-scale datasets, including genomics, proteomics<\/a>, and clinical trial data, to identify new therapeutic indications for existing compounds. Advanced algorithms support drug-target interaction mapping and biomarker discovery, accelerating translational research. For instance, in January 2025, NVIDIA and Innophore partnered to launch CavitOmiX, an AI-driven drug safety screening platform. Innophore\u2019s AI-driven CavitOmiX platform, powered by NVIDIA, significantly supports drug repurposing by analyzing protein binding sites to identify hidden therapeutic opportunities between existing drugs and new targets.<\/p>\n The services segment is expected to grow at the fastest CAGR during the forecast period. The services segment encompasses specialized offerings that support the deployment, customization, and optimization of AI solutions for drug repurposing. These include data curation, annotation, algorithm training, model validation, and integration of AI tools into existing research workflows. Service providers also assist with regulatory compliance, ensuring AI-driven predictions align with evolving guidelines for drug development. Moreover, services are increasingly focused on collaborative projects that combine domain expertise in biology with advanced computational capabilities, propelling market growth further.<\/p>\n Technology Insights<\/p>\n The machine learning\/deep leaning segment accounted for the largest revenue share of 46.01% in 2024. These technologies analyze genomic data, clinical trial results, molecular structures, and real-world patient records to identify unrecognized correlations. Deep learning models, especially neural networks, improve prediction accuracy by capturing non-linear relationships within complex biological systems. Such methods enable the rapid screening of thousands of compounds against multiple disease targets, significantly accelerating discovery timelines.<\/p>\n The generative AI & large language models (LLMs) segment is anticipated to register the fastest growth from 2025 to 2033. The Generative AI and LLMs segment is transforming drug repurposing by enabling rapid hypothesis generation and molecular design through advanced natural language and generative modeling capabilities. LLMs are able to analyze vast biomedical literature, clinical trial records, and omics data to identify links between existing drugs and new disease indications. Generative AI enhances this process by designing novel molecular variations or predicting drug-disease interactions with high precision. These tools reduce the time spent on manual curation, creating a scalable framework for discovering repurposing opportunities.<\/p>\n Application Insights<\/p>\n
![\"AI](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/09\/ai-drug-repurposing-market-share.webp.webp\" "\\"AI")
<\/p>\n![\"AI](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/09\/ai-drug-repurposing-market-trends-by-region.webp.webp\" "\\"AI")
<\/p>\n